Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pyxis Oncology (PYXS) Cash from Financing Activities: 2020-2024

Historic Cash from Financing Activities for Pyxis Oncology (PYXS) over the last 5 years, with Dec 2024 value amounting to $59.3 million.

  • Pyxis Oncology's Cash from Financing Activities fell 100.48% to -$8,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.8 million, marking a year-over-year change of. This contributed to the annual value of $59.3 million for FY2024, which is 900.61% up from last year.
  • As of FY2024, Pyxis Oncology's Cash from Financing Activities stood at $59.3 million, which was up 900.61% from $5.9 million recorded in FY2023.
  • Pyxis Oncology's Cash from Financing Activities' 5-year high stood at $304.0 million during FY2021, with a 5-year trough of $35,000 in FY2020.
  • Over the past 3 years, Pyxis Oncology's median Cash from Financing Activities value was $5.9 million (recorded in 2023), while the average stood at $21.8 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first skyrocketed by 868,597.14% in 2021, then tumbled by 99.94% in 2022.
  • Pyxis Oncology's Cash from Financing Activities (Yearly) stood at $35,000 in 2020, then surged by 868,597.14% to $304.0 million in 2021, then crashed by 99.94% to $183,000 in 2022, then spiked by 3,139.89% to $5.9 million in 2023, then surged by 900.61% to $59.3 million in 2024.